Altamira Therapeutics Statistics
Total Valuation
Altamira Therapeutics has a market cap or net worth of 407,503. The enterprise value is 769,482.
| Market Cap | 407,503 |
| Enterprise Value | 769,482 |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Altamira Therapeutics has 3.40 million shares outstanding. The number of shares has increased by 1,503.64% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 3.40M |
| Shares Change (YoY) | +1,503.64% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.61% |
| Owned by Institutions (%) | 0.50% |
| Float | 2.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.05 |
| P/TBV Ratio | 0.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.28 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.43, with a Debt / Equity ratio of 0.07.
| Current Ratio | 0.43 |
| Quick Ratio | 0.15 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.80 |
Financial Efficiency
Return on equity (ROE) is -368.78% and return on invested capital (ROIC) is -99.80%.
| Return on Equity (ROE) | -368.78% |
| Return on Assets (ROA) | -57.15% |
| Return on Capital (ROIC) | -99.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -270,088 |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.25% in the last 52 weeks. The beta is 2.41, so Altamira Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 2.41 |
| 52-Week Price Change | -96.25% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 1.09 |
| Relative Strength Index (RSI) | 16.63 |
| Average Volume (20 Days) | 258,707 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.38 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.85M |
| Pretax Income | -7.91M |
| Net Income | -2.70M |
| EBITDA | n/a |
| EBIT | -6.85M |
| Earnings Per Share (EPS) | -1.91 |
Balance Sheet
The company has 65,455 in cash and 427,437 in debt, giving a net cash position of -361,982 or -0.11 per share.
| Cash & Cash Equivalents | 65,455 |
| Total Debt | 427,437 |
| Net Cash | -361,982 |
| Net Cash Per Share | -0.11 |
| Equity (Book Value) | 6.32M |
| Book Value Per Share | 2.37 |
| Working Capital | -703,852 |
Cash Flow
| Operating Cash Flow | -7.58M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Altamira Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,503.64% |
| Shareholder Yield | -1,503.64% |
| Earnings Yield | -1,591.44% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on December 13, 2023. It was a reverse split with a ratio of 0.05.
| Last Split Date | Dec 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |